Skip to main content

Continuous Disinfectant Spray Limits Airborne Pathogens


July 10, 2012 (Bangkok, Thailand) — A continuous aerosol spray with a nontoxic alcohol-free disinfectant can control airborne pathogens in patient areas of hospitals and in laboratories.
S.J. Abraham, MD, from the Second Department of Surgery, Faculty of Medicine, Yamanashi University, in Japan, and the Nichi-In Centre for Regenerative Medicine in Chennai, India, presented the microbiologic results of a study here at the 15th International Congress on Infectious Diseases. Researchers tested a spray containing citric acid anhydride, citric acid natrium, and cetylpyridinium chloride (sold as Clinister in Japan). These chemicals are either food additives or have been used for several years in the food industry in Japan.
The chemicals are "delivered in a 5 μm spray using a special humidifier and nebulizer kind of equipment" to remove environmental pathogens from the air, Dr. Abraham told Medscape Medical News. They come as a powder that is mixed with potable (preferably sterile) water. "In an environment of approximately 300 square feet, it brings down most of the disease-causing pathogenic organisms," he said. These include bacteria, viruses, and fungi.
The 5 μm droplets produced in the ultrasonic humidifier can entangle smaller particles and remove them from the air. Airborne bacteria are in the order of 0.8 μm, and viruses are about 0.1 μm.
To test the effectiveness of the spray against common airborne organisms, the researchers inoculated soybean–casein digest agar plates with Escherichia coli or Staphylococcus aureus bacteria, or with Candida albicans orAspergillus flavus fungi. Control plates and plates exposed to the spray mist were incubated at 37 °C.
After 18 hours of incubation, the control plates containing the bacteria showed confluent growth, but the ones exposed to the spray mist showed no growth or much reduced growth. The mist also inhibited the growth of the fungi to some degree.
The researchers concluded that continuous spraying of the mist should be considered for the disinfection of high-risk healthcare settings, such as intensive care units, old age homes, operating rooms, burn units, and bone marrow transplant units — wherever immunocompromised patients are.
It can also be used in places like airports during pandemics, Dr. Abraham explained. "Even H5N3 [the influenza virus] can be dealt with this way."
He noted that options for air disinfection are limited. Hydrogen peroxide or fumigants of potassium permanganate–formalin are widely used, but these can irritate the eyes and nose, and some might be carcinogenic.
Dr. Abraham explained that the method under study uses compounds that are food additives, that are nontoxic and nonallergenic when contacted or ingested. The continuous use of the spray appears to be safe, and it has a residual antimicrobial effect on surfaces.
As always, the possibility of microbial resistance remains. "They are living organisms...so we need to keep chasing them," Dr. Abraham said.
Hans Liu, MD, professor of medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, and an infectious disease specialist at Bryn Mawr Hospital in Pennsylvania, who was not involved in the study, toldMedscape Medical News that he sees potential value in this spray.
"We have a lot of people with resistant organisms. The [extended-spectrum beta-lactamase]-producing Gram-negative rods come to mind, as do methicillin-resistant Staphylococcus aureus and C difficile, of course," he said. "We try very hard to disinfect rooms; the problem is that a lot of time, the best cleaning is done after the patient is discharged."
More irritating disinfecting compounds cannot be used in the presence of people because of the risk for toxic or allergic reactions.
Dr. Liu said that he does not have any direct experience with this system, "but it probably has antimicrobial activity; you're basically trying to kill the bugs as they're being shed or spread into the environment. It's a very interesting thought."
However, he wonders whether the chemical components are entirely without risk for toxic effects or irritation, what the cost will be, and whether the mist might select for resistant organisms by eliminating more sensitive ones from the immediate environment. He said that Pseudomonas in general is more resistant to germicidal agents thanEscherichia coli, "so I think you have to do the study.... Of course, the eventual proof will be if you use it in a controlled trial with patients, one group versus another, and if the group that uses this spray does a lot better in terms of the frequency of infections, the type of infecting organisms, and length of stay in the hospital — then you may be onto something."
When informed that the powder for the mist costs about $8 a day, he pointed out that such an amount "in the United States is negligible or acceptable. In a lot of Third World countries, that's a lot of money. And of course, [there is the cost of] the device."
Dr. Liu summed up the situation by saying that "we're struggling...to decrease the frequency of infections in the hospital or healthcare setting, especially multiply resistant organisms...so we're more than willing to look at innovative ways of protecting our patients."
Funding for various aspects of this or related studies was provided by Technology Development at Separator System, Kogyo and by Miyoshino Seiyaku Co., Ltd. Dr. Abraham reports being a consultant to a company that promotes the product. Dr. Liu reports serving on speakers bureaus of Forest Laboratories and Daiichi Sankyo.
15th International Congress on Infectious Diseases (ICID): Abstract 54.001. Presented June 16, 2012.

Comments

  1. I'm truly enjoying thе design and laуοut of your ωebsite.

    It's a veгy еаsy on the eyes which makes it much more plеasant for me to cоme hеre аnd visit more οften.
    Dіd you hirе out a deνelοper to creaye your
    theme? Exсeptional work!

    Αlso ѵisit mу blog :: hostesy ()

    ReplyDelete
  2. Spоt on with this wгіte-up, I tгulу
    think this ωeb site nееds a lot mοre attеntion.
    I'll рrobably be baсκ again to see more, thаnκs for the іnformatіοn!


    Feel freе to visit my websіte ... kafle piecowe

    ReplyDelete
  3. I love what you gus tend to bе up too. Тhis sort
    of cleѵer wοrk andd rеportіng!
    Keеp uup the excellent woгks guys I'vе
    included you guys to my oωn blοgroll.


    mу homepаge /

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n